Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

    Melrose Industries

    MCap

    GBP8,167m

    Last close

    GBP6.70

    ▲ 74.80 (12.57%)

    OpGen

    MCap

    USD7m

    Last close

    USD0.49

    ▲ 0.05 (11.62%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Basilea Pharmaceutica (SIX: BSLN)

Last close As at 20/05/2024

CHF43.65

▲ −0.65 (−1.47%)

Market capitalisation

CHF584m

Basilea Pharmaceutica is focused on treating infectious diseases; marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA broad-spectrum antibiotic). In late 2023, it expanded its pipeline to include BAL2062 (antifungal), tonabacase (antibiotic) and Phase III-ready fosmanogepix (antifungal).

There is an ever-increasing need for therapeutic agents that are efficacious against drug-resistant strains of bacteria (eg MRSA) or fungi. Hence the opportunities for Zevtera and Cresemba could be significant.

Latest Insights

View More

Healthcare | Flash note

Basilea Pharmaceutica — Cresemba milestone payments continue to roll in

Healthcare | Update

Basilea Pharmaceutica — Need for innovation against severe infections

Healthcare | Flash note

Basilea Pharmaceutica — CARB-X grant for preclinical programs

Healthcare | Update

Basilea Pharmaceutica — Zevtera crosses key US regulatory hurdle
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • Adesh Kaul

    CFO

  • David Veitch

    CEO

  • Dung Tran

    Investor relations coordinator

Balance Sheet

Forecast net debt (CHFm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 7.8 20.1 (3.7)
Relative 1.0 13.7 (7.1)
52 week high/low CHF48.6/CHF32.2

Financials

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in the Asia-Pacific region and China. This is the second FY24 milestone payment for the region and is incremental to the payment received in March. We note that, according to the latest available data, total in-market sales of Cresemba amounted to US$473m in the 12 months ending December 2023, representing a +26% year-on-year increase. Basilea is preparing to launch its Phase III programme for fosmanogepix, a broad-spectrum antifungal therapy, with the first of two Phase III trials expected to initiate in mid-2024. The company also made positive regulatory and operational strides with its lead antibiotic asset, Zevtera (following FDA approval in April 2024), and we eagerly await the announcement of a potential US commercial partner.

Y/E Dec Revenue (CHFm) EBITDA (CHFm) PBT (CHFm) EPS (CHFc) P/E (x) P/CF (x)
2022A 147.8 19.6 12.3 104.10 42.6 N/A
2023A 157.6 20.8 10.8 89.66 49.4 N/A
2024E 187.2 34.0 28.0 233.65 19.0 N/A
2025E 209.1 37.9 32.3 269.24 16.5 N/A

Research

Update

Healthcare

Basilea Pharmaceutica — Need for innovation against severe infections

Flash note

Healthcare

Basilea Pharmaceutica — CARB-X grant for preclinical programs

Healthcare

Flash note

Basilea Pharmaceutica — Cresemba milestone payments continue to roll in
View All

Further insights

insight

Healthcare

Antibiotic resistance

insight

Healthcare

Antibiotics

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

sromanoff@edisongroup.com 020 3077 5700
Read latest

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free